Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-APEX: REGN7508 vs apixaban vs enoxaparin for VTE prophylaxis after total knee arthroplasty
jRCT2051250082Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of REGN7508 in venous thromboembolism (VTE) (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Incidence of composite asymptomatic or symptomatic venous thromboembolism (including VTE-related death). Started Oct 2025; status: recruiting.
02
Drugs
REGN7508
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on jRCT2051250082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250082.